Lisa M Kaminskas1, Cornelia B Landersdorfer2, Robert J Bischof3, Nathania Leong3, Jibriil Ibrahim3, Andrew N Davies3,4, Stephen Pham5, Steven Beck5, A Bruce Montgomery5, Mark W Surber6. 1. School of Biomedical Sciences, University of Queensland, QLD, St Lucia, 4072, Australia. L.kaminskas@uq.edu.au. 2. Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia. 3. Allergenix Pty Ltd, Melbourne, VIC, 3051, Australia. 4. Biomedicine Discovery Institute, Monash University, Peninsula Campus, Frankston, VIC, 3199, Australia. 5. Avalyn Pharma Inc., 701 Pike Street, Suite 1500, Seattle, WA, 98101, USA. 6. Avalyn Pharma Inc., 701 Pike Street, Suite 1500, Seattle, WA, 98101, USA. msurber@avalynpharma.com.
Abstract
PURPOSE: Inhaled delivery of pirfenidone to the lungs of patients with idiopathic pulmonary fibrosis holds promise to eliminate oral-observed side effects while enhancing efficacy. This study aimed to comprehensively describe the pulmonary pharmacokinetics of inhaled aerosol pirfenidone in healthy adult sheep. METHODS: Pirfenidone concentrations were evaluated in plasma, lung-derived lymph and epithelial lining fluid (ELF) with data subjected to non-compartmental pharmacokinetic analysis. RESULTS: Compartmental pharmacokinetic evaluation indicated that a 49 mg lung-deposited dose delivered an ELF Cmax of 62 ± 23 mg/L, and plasma Cmax of 3.1 ± 1.7 mg/L. Further analysis revealed that plasma pirfenidone reached Tmax faster and at higher concentrations than in lymph. These results suggested inhaled pirfenidone was cleared from the alveolar interstitium via blood faster than the drug could equilibrate between the lung interstitial fluid and lung lymphatics. However, the data also suggested that a 'reservoir' of pirfenidone feeds into lung lymph at later time points (after it has largely been cleared from plasma), prolonging lung lymphatic exposure. CONCLUSIONS: This study indicates inhaled pirfenidone efficiently deposits in ELF and is cleared from the lungs by initial absorption into plasma, followed by later equilibrium with lung interstitial and lymph fluid.
PURPOSE: Inhaled delivery of pirfenidone to the lungs of patients with idiopathic pulmonary fibrosis holds promise to eliminate oral-observed side effects while enhancing efficacy. This study aimed to comprehensively describe the pulmonary pharmacokinetics of inhaled aerosol pirfenidone in healthy adult sheep. METHODS:Pirfenidone concentrations were evaluated in plasma, lung-derived lymph and epithelial lining fluid (ELF) with data subjected to non-compartmental pharmacokinetic analysis. RESULTS: Compartmental pharmacokinetic evaluation indicated that a 49 mg lung-deposited dose delivered an ELF Cmax of 62 ± 23 mg/L, and plasma Cmax of 3.1 ± 1.7 mg/L. Further analysis revealed that plasma pirfenidone reached Tmax faster and at higher concentrations than in lymph. These results suggested inhaled pirfenidone was cleared from the alveolar interstitium via blood faster than the drug could equilibrate between the lung interstitial fluid and lung lymphatics. However, the data also suggested that a 'reservoir' of pirfenidone feeds into lung lymph at later time points (after it has largely been cleared from plasma), prolonging lung lymphatic exposure. CONCLUSIONS: This study indicates inhaled pirfenidone efficiently deposits in ELF and is cleared from the lungs by initial absorption into plasma, followed by later equilibrium with lung interstitial and lymph fluid.
Authors: Cornelia B Landersdorfer; Tri-Hung Nguyen; Linh Thuy Lieu; Gary Nguyen; Robert J Bischof; Els N Meeusen; Jian Li; Roger L Nation; Michelle P McIntosh Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: Souheil El-Chemaly; Daniela Malide; Enrique Zudaire; Yoshihiko Ikeda; Benjamin A Weinberg; Gustavo Pacheco-Rodriguez; Ivan O Rosas; Marta Aparicio; Ping Ren; Sandra D MacDonald; Hai-Ping Wu; Steven D Nathan; Frank Cuttitta; J Philip McCoy; Bernadette R Gochuico; Joel Moss Journal: Proc Natl Acad Sci U S A Date: 2009-02-23 Impact factor: 11.205
Authors: Lisa M Kaminskas; Jagannath Kota; Victoria M McLeod; Brian D Kelly; Peter Karellas; Christopher Jh Porter Journal: J Control Release Date: 2009-08-15 Impact factor: 9.776
Authors: Jun Keng Khoo; A Bruce Montgomery; Kelly L Otto; Mark Surber; Jessica Faggian; Jason D Lickliter; Ian Glaspole Journal: J Aerosol Med Pulm Drug Deliv Date: 2019-01-30 Impact factor: 2.849
Authors: Jibriil P Ibrahim; Shadabul Haque; Robert J Bischof; Andrew K Whittaker; Michael R Whittaker; Lisa M Kaminskas Journal: Front Pharmacol Date: 2022-06-02 Impact factor: 5.988